Efficacy of radiofrequency ablation combined with sorafenib for treating liver cancer complicated with portal hypertension and prognostic factors

Table 3 Comparison of liver cancer marker levels before and after treatment between the two groups (mean ± SD)

Group	AFP (ug/L)		GPC-3 (ng/mL)		AFP-L3 (ng/L)
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Research group (n = 50)	645.88 ± 56.05	463.12 ± 40.45a	11.52 ± 2.88	6.46 ± 1.43a	1751.54 ± 214.99	867.26 ± 153.14a
Control group (n = 50)	655.80 ± 53.69	563.21 ± 41.46a	11.89 ± 2.58	4.84 ± 1.26a	1787.74 ± 177.19	1179.48 ± 175.10a
t value	0.904	12.220	0.665	5.975	0.919	9.491
P value	0.368	< 0.001	0.508	< 0.001	0.360	< 0.001

^aP < 0.05 when compared to the same group prior to treatment.

AFP: Alpha-fetoprotein; GPC-3: Glypican-3.